MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
3.200
-0.050
-1.54%
After Hours: 3.260 +0.06 +1.88% 17:05 05/22 EDT
OPEN
3.270
PREV CLOSE
3.250
HIGH
3.275
LOW
3.170
VOLUME
321.56K
TURNOVER
0
52 WEEK HIGH
4.450
52 WEEK LOW
1.430
MARKET CAP
114.72M
P/E (TTM)
-1.0080
1D
5D
1M
3M
1Y
5Y
Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis
Healthcare Eli Lilly inks radiopharma deal worth up to $ with Aktis Oncology. Aktis will receive a $60M upfront payment. Eli Lilly will leverage Aktis’ radiopharmaceutical platform to develop cancer-targeting drugs.
Seeking Alpha · 1d ago
Cellectar Biosciences: Still Working On That Hit (Maintain Buy)
Cellectar Biosciences, Inc. Is focused on developing a radiopharmaceutical for Waldenstrom's macroglobulinemia, a type of non-Hodgkin lymphoma. The company has positive topline data from a pivotal study for the disease. Cellectar has a strong pipeline and potential for commercialization, but the timeline for approval is not guaranteed.
Seeking Alpha · 2d ago
Weekly Report: what happened at CLRB last week (0513-0517)?
Weekly Report · 2d ago
Buy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug Pipeline
TipRanks · 05/15 18:05
CLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024
Cellectar Biosciences reported earnings per share of -74 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -72 cents. Cellectar reported results for the fourth quarter of 2016.
Investorplace · 05/14 14:53
Cellectar Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Cellectar Biosciences Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 74 cents per share; analysts expected a loss of 56 cents. The average analyst rating on the shares is "strong buy" for the company.
Reuters · 05/14 13:52
Cellectar Biosciences Inc Loss At -$21.58 Mln In Q1
NASDAQ · 05/14 11:19
Cellectar Biosciences GAAP EPS of -$0.74 misses by $0.18
Seeking Alpha · 05/14 10:44
More
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).

Webull offers Cellectar Biosciences Inc stock information, including NASDAQ: CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.